Is Wellbutrin (bupropion) appropriate as first‑line therapy for a patient with depression, prominent anxiety, and a history of substance‑use disorder?

Bupropion for Depression, Anxiety, and Substance‑Use History

Bupropion is generally not recommended as first‑line therapy for patients with prominent anxiety symptoms, but it is appropriate for depression with comorbid substance‑use disorder—particularly for patients who smoke or have alcohol dependence—provided anxiety is not severe or agitated. 1

---

Clinical Decision Algorithm

Step 1: Screen for absolute contraindications

Before prescribing bupropion, confirm the patient does not have:

• Seizure disorder or any condition lowering seizure threshold (e.g., eating disorders, abrupt alcohol/benzodiazepine withdrawal, brain tumor, head trauma) 1, 2
• Current MAOI use or within 14 days of discontinuation 1, 2
• Uncontrolled hypertension 1, 2
• Moderate‑to‑severe hepatic or renal impairment (requires dose reduction to ≤150 mg/day) 1, 2

If any contraindication is present, choose an SSRI (e.g., sertraline, escitalopram) instead. 1

---

Step 2: Assess the severity and type of anxiety

• If anxiety is prominent, severe, or the patient is agitated: The American Academy of Family Physicians explicitly states that bupropion should not be used in agitated patients and is contraindicated in patients with agitated depression or prominent anxiety symptoms. 1 In this scenario, start an SSRI or SNRI as first‑line therapy. 1

• If anxiety is mild‑to‑moderate and occurs as part of a depressive syndrome: Bupropion is appropriate, especially when the patient also has apathy, low energy, or fatigue. 1 High‑quality evidence from the STAR*D trial shows that baseline anxiety does not diminish bupropion's comparative efficacy versus other second‑generation antidepressants. 1

• If the patient has comorbid substance use (smoking, alcohol, stimulants): Bupropion is particularly beneficial because it addresses both depression and substance cravings through complementary dopaminergic/noradrenergic mechanisms. 1, 2

---

Step 3: Initiate bupropion with careful titration

Dosing schedule:

• Start bupropion SR 150 mg once daily for 3 days, then increase to 150 mg twice daily (total 300 mg/day) if tolerated. 1, 2
• Administer the second dose before 3 PM to minimize insomnia. 1, 2
• Maximum dose: 400 mg/day for SR formulation or 450 mg/day for XL formulation. 2 Do not exceed these limits to maintain seizure risk at ≈0.1%. 1, 2

For older adults or patients on multiple medications:

• Start with 37.5 mg once daily in the morning, increase by 37.5 mg every 3 days as tolerated, targeting 150 mg twice daily (maximum 300 mg/day). 1, 2

---

Step 4: Monitor closely during the first 1–2 weeks

• Assess for suicidal ideation, agitation, irritability, or unusual behavioral changes within 1–2 weeks of initiation. 1, 2 The risk of suicide attempts is highest during the first 1–2 months of antidepressant therapy, especially in patients <24 years old. 1, 2
• Monitor blood pressure and heart rate, especially in the first 12 weeks, as bupropion can cause modest elevations. 1, 2
• Watch for worsening anxiety or agitation. If anxiety increases significantly, consider switching to an SSRI. 1

---

Step 5: Evaluate response at 6–8 weeks

• Allow 6–8 weeks at therapeutic doses (300 mg/day) before determining treatment response. 1, 2, 3
• If inadequate response: Consider augmenting with an SSRI (e.g., sertraline 50–200 mg/day or escitalopram 10–20 mg/day) rather than switching. 1, 3 Augmentation with an SSRI addresses both serotonergic and dopaminergic/noradrenergic pathways and has lower discontinuation rates (12.5%) compared to buspirone augmentation (20.6%, P < 0.001). 1
• If adequate response: Continue bupropion for at least 4–9 months for a first depressive episode, or ≥1 year for recurrent depression. 1

---

Advantages of Bupropion in Substance‑Use Populations

• Smoking cessation: Bupropion increases 12‑month abstinence by roughly 9–10 percentage points compared to placebo (≈19% quit rate vs 11% with placebo). 1, 2 Begin bupropion 1–2 weeks before the target quit date and continue for 7–12 weeks after quitting. 1, 2
• Alcohol dependence: Combining bupropion with naltrexone addresses both depressive symptoms and alcohol cravings through complementary mechanisms. 1 Naltrexone is a first‑line option for alcohol dependence, and the combination is safe and effective. 1
• Stimulant use (methamphetamine, cocaine): Bupropion has demonstrated efficacy for methamphetamine dependence, particularly in patients with low‑to‑moderate baseline use. 1

---

Key Safety Considerations

• Seizure risk: At 300 mg/day, the seizure rate is approximately 0.1% (1 in 1,000). 1, 2 Risk increases with doses >450 mg/day, rapid titration, or predisposing conditions (eating disorders, abrupt alcohol/benzodiazepine withdrawal). 1, 2
• Anxiety exacerbation: Bupropion's activating properties can worsen anxiety in some patients, particularly at higher doses. 4 If anxiety worsens, reduce the dose or switch to an SSRI. 1
• Sexual dysfunction: Bupropion has significantly lower rates of sexual dysfunction compared to SSRIs, making it advantageous for patients concerned about this side effect. 1, 2
• Weight: Bupropion is associated with minimal weight gain or even weight loss, unlike many other antidepressants. 1, 2

---

Common Pitfalls to Avoid

• Do not use bupropion in agitated or highly anxious patients. 1 The American Academy of Family Physicians explicitly contraindicates bupropion in agitated depression. 1
• Do not skip the intensive monitoring window during weeks 1–2, as this period carries the highest risk for emergent suicidal ideation. 1, 2
• Do not exceed 450 mg/day, as seizure risk rises markedly above this threshold. 1, 2
• Do not combine with MAOIs or initiate within 14 days of MAOI discontinuation. 1, 2
• Do not discontinue abruptly—taper gradually to minimize withdrawal symptoms. 1

---

When to Choose an SSRI Instead

If the patient has prominent, severe, or agitated anxiety, start an SSRI (e.g., sertraline 50–200 mg/day or escitalopram 10–20 mg/day) as first‑line therapy. 1 SSRIs are generally preferred for anxious depression and have comparable overall efficacy to bupropion (remission rates 42–49%). 1 However, SSRIs have higher rates of sexual dysfunction and weight gain compared to bupropion. 1, 2